Date | Time | Source | Headline | Symbol | Company |
05/23/2024 | 5:05PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:CRM | Salesforce Inc |
05/23/2024 | 5:05PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PODD | Insulet Corporation |
05/23/2024 | 5:05PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PRVA | Privia Health Group Inc |
05/23/2024 | 5:05PM | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:TCPC | BlackRock TCP Capital Corporation |
05/23/2024 | 5:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:HOOK | HOOKIPA Pharma Inc |
05/23/2024 | 5:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CADL | Candel Therapeutics Inc |
05/23/2024 | 5:05PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:EVAX | Evaxion Biotech AS |
05/23/2024 | 5:05PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PRVA | Privia Health Group Inc |
05/23/2024 | 5:05PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:XEL | Xcel Energy Inc |
05/23/2024 | 5:05PM | Business Wire | Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting | | |
05/23/2024 | 5:05PM | GlobeNewswire Inc. | Elcora Announces Share Consolidation | TSXV:ERA | Elcora Advanced Materials Corp |
05/23/2024 | 5:05PM | GlobeNewswire Inc. | Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024 | NASDAQ:AFMD | Affimed NV |
05/23/2024 | 5:05PM | Business Wire | Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms | NYSE:BMY | Bristol Myers Squibb Co |
05/23/2024 | 5:05PM | PR Newswire (US) | EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting | | |
05/23/2024 | 5:05PM | PR Newswire (US) | Landmark Study from Mercy BioAnalytics and University College London Demonstrates Significant Improvement Over CA125 and Ultrasound for Ovarian Cancer Screening | | |
05/23/2024 | 5:05PM | PR Newswire (US) | IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma | NASDAQ:IDYA | IDEAYA Biosciences Inc |
05/23/2024 | 5:05PM | PR Newswire (US) | ALIMENTATION COUCHE-TARD TO RELEASE RESULTS FOR ITS FOURTH QUARTER AND FISCAL YEAR 2024 ON JUNE 25, 2024 | TSX:ATD | Alimentation Couche Tard Inc |
05/23/2024 | 5:05PM | PR Newswire (Canada) | ALIMENTATION COUCHE-TARD TO RELEASE RESULTS FOR ITS FOURTH QUARTER AND FISCAL YEAR 2024 ON JUNE 25, 2024 | TSX:ATD | Alimentation Couche Tard Inc |
05/23/2024 | 5:05PM | GlobeNewswire Inc. | FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology | NASDAQ:FGEN | FibroGen Inc |
05/23/2024 | 5:05PM | PR Newswire (Canada) | ALIMENTATION COUCHE-TARD DIFFUSERA LE 25 JUIN PROCHAIN LES RÉSULTATS DE SON QUATRIÈME TRIMESTRE ET DE SON EXERCICE 2024 | TSX:ATD | Alimentation Couche Tard Inc |
05/23/2024 | 5:05PM | Business Wire | TelevisaUnivision Announces Pricing of $1.0 Billion Debt | | |
05/23/2024 | 5:05PM | GlobeNewswire Inc. | Elcora Announces Share Consolidation | ELM | |
05/23/2024 | 5:05PM | GlobeNewswire Inc. | Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meet | NASDAQ:CMPX | Compass Therapeutics Inc |
05/23/2024 | 5:05PM | GlobeNewswire Inc. | Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer | NASDAQ:COGT | Cogent Biosciences Inc |
05/23/2024 | 5:05PM | Business Wire | Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting | NASDAQ:BCYC | Bicycle Therapeutics PLC |
05/23/2024 | 5:05PM | GlobeNewswire Inc. | I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024 | NASDAQ:IMAB | I MAB |
05/23/2024 | 5:05PM | PR Newswire (US) | Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting | NASDAQ:BPMC | Blueprint Medicines Corporation |
05/23/2024 | 5:05PM | Business Wire | TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany | NASDAQ:NVCR | NovoCure Ltd |
05/23/2024 | 5:04PM | GlobeNewswire Inc. | Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 | NASDAQ:CGEM | Cullinan Therapeutics Inc |
05/23/2024 | 5:04PM | Edgar (US Regulatory) | Form 3/A - Initial statement of beneficial ownership of securities: [Amend] | NASDAQ:PRVA | Privia Health Group Inc |